公开(公告)号：EP3416656A1

公开(公告)日：2018-12-26

申请号：EP17752574.8

申请日：2017-02-17

申请人： Recce Pharmaceuticals Ltd

发明人： MELROSE, Graham John Hamilton ,  DILIZIA, Michele Keryn

IPC分类号： A61K31/765 ,  A61K31/78 ,  C08G2/00 ,  C08G2/18 ,  A61P31/12

CPC分类号： A61K31/78 ,  A61K9/0019 ,  A61K9/0053 ,  A61K9/0073 ,  A61K9/20 ,  A61K9/48 ,  A61P31/16 ,  A61P31/18 ,  A61P31/22

摘要： A method of treatment of viral infection in a subject comprising administering to the subject a copolymer comprising an acrolein derived segment or a polyacrolein oligomer segment and a polyalkylene glycol oligomer segment, the copolymer having a molecular weight of no more than 1500 Daltons.

公开(公告)号：EP3405497A2

公开(公告)日：2018-11-28

申请号：EP17707109.9

申请日：2017-01-20

申请人： Mabquest SA

发明人： PANTALEO, Giuseppe ,  FENWICK, Craig

IPC分类号： C07K16/28 ,  A61K39/395

CPC分类号： C07K16/2803 ,  A61K39/39541 ,  A61K39/39558 ,  A61K2039/507 ,  A61P31/18 ,  A61P35/00 ,  C07K16/2818 ,  C07K2317/24 ,  C07K2317/33 ,  C07K2317/34 ,  C07K2317/75 ,  C07K2317/76

摘要： This disclosure relates to binding agents with specificity for programmed cell death 1 (PD-1) and to methods for using the same to treat, prevent and/or ameliorate an infectious disease (e.g., human immunodeficiency virus (HIV)), cancer and/or autoimmunity. In addition, this disclosure identifies a novel binding patch (“P2”) on PD-1 that is linked with a previously unidentified functional activity of PD-1 that is distinct from the interaction site involved with either the PD-L1 or PD-L2 ligands. Furthermore, we demonstrate that antibodies that interact with this region of PD-1 are able to act as antagonists of PD-1 and that this antagonism is further enhanced with the addition of antibodies that act through the blockade of the PD-1/PD-L1/L2 interaction.

公开(公告)号：EP3383863A1

公开(公告)日：2018-10-10

申请号：EP16806294.1

申请日：2016-12-01

申请人： ViiV Healthcare UK Limited

发明人： JOHNS, Brian Alvin ,  VELTHUISEN, Emile Johann ,  WEATHERHEAD, Jason Gordon

IPC分类号： C07D405/04 ,  C07D209/44 ,  A61K31/4035 ,  A61P31/18

CPC分类号： C07D405/04 ,  A61P31/18 ,  C07D209/44

摘要： Compounds of Formula (I) are disclosed and methods of treating viral infections with compositions comprising such compounds.

公开(公告)号：EP3377066A1

公开(公告)日：2018-09-26

申请号：EP16866886.1

申请日：2016-11-11

申请人： Merck Sharp & Dohme Corp.

发明人： GRAHAM, Thomas, H. ,  YU, Tao ,  WADDELL, Sherman, T. ,  MCCAULEY, John, A. ,  STAMFORD, Andrew ,  LIU, Wensheng ,  GROBLER, Jay, A. ,  XU, Libo

IPC分类号： A61K31/53 ,  A61K31/495 ,  A61K31/4985 ,  C07D295/00 ,  C07D401/02 ,  C07D403/02

CPC分类号： A61K31/675 ,  A61K31/34 ,  A61K31/426 ,  A61K31/44 ,  A61K31/513 ,  A61K31/52 ,  A61K31/535 ,  A61K31/683 ,  A61K31/7068 ,  A61K45/06 ,  A61K2300/00 ,  A61P31/18 ,  C07D471/04 ,  C07F9/6561

摘要： The present invention relates to Amido-Substituted Pyridotriazine Derivatives of Formula (I): (I) and pharmaceutically acceptable salts thereof, wherein B, X, Y, R, R1, R2 and R10 are as defined herein. The present invention also relates to compositions comprising at least one Amido-Substituted Pyridotriazine Derivative, and methods of using the Amido-Substituted Pyridotriazine Derivatives for treating or preventing HIV infection in a subject.

公开(公告)号：EP3368902A1

公开(公告)日：2018-09-05

申请号：EP16790916.7

申请日：2016-10-26

申请人： INSERM (Institut National de la Santé et de la Recherche Médicale) ,  Centre National de la Recherche Scientifique (CNRS) ,  Université Paul Sabatier Toulouse III ,  Université Paris Diderot - Paris 7

发明人： JABRANE-FERRAT, Nabila ,  SIEWIERA, Johan ,  AL-DACCAK, Reem

IPC分类号： G01N33/569 ,  C12Q1/68 ,  G01N33/574

CPC分类号： G01N33/5023 ,  A61P31/16 ,  A61P31/18 ,  C07K16/244 ,  C12Q1/6881 ,  C12Q1/6886 ,  C12Q2600/156 ,  G01N33/56966 ,  G01N33/56972 ,  G01N33/56988 ,  G01N33/56994 ,  G01N33/574 ,  G01N2800/245 ,  G01N2800/26 ,  G01N2800/50 ,  G01N2800/52

摘要： The invention relates to a method for monitoring the immunological profile of a subject, comprising measuring the expressions of each member of the group consisting of NKp30a, NKp30b, NKp30c, NKp44b and NKp44c, in a biological sample of said subject, wherein: if the expressions of NKp30a, NKp30b, and NKp44b are the three highest among said group, then said subject has a responsive profile; or if the expressions of NKp30c and NKp44c are the two highest among said group, then said subject has an unresponsive profile.

公开(公告)号：EP3368557A1

公开(公告)日：2018-09-05

申请号：EP16790553.8

申请日：2016-10-28

申请人： Affibody AB

发明人： WAHLBERG, Elisabet

IPC分类号： C07K14/705

CPC分类号： C07K14/70532 ,  A61K38/1774 ,  A61P31/18 ,  A61P31/20 ,  A61P35/02 ,  C07K14/745 ,  C07K2319/00

摘要： The present disclosure relates to a class of engineered polypeptides having a binding affinity for programmed death-ligand 1 (PD-L1), and provides a PD-L1 binding polypeptide comprising the sequence ERTX4AX6WEIX10X11LPNLX16X17X18QX20GAFIX25X26LHD. The present disclosure also relates to the use of such a PD-L1 binding polypeptide a prognostic and/or diagnostic agent as well as a therapeutic agent.

公开(公告)号：EP3353158A1

公开(公告)日：2018-08-01

申请号：EP16771000.3

申请日：2016-09-22

申请人： GlaxoSmithKline Intellectual Property (No. 2) Limited

发明人： JOHNS, Brian Alvin

IPC分类号： C07D279/12 ,  C07J63/00 ,  C07D211/96 ,  A61K31/56 ,  A61P31/18

CPC分类号： C07J63/008 ,  A61K31/58 ,  A61K45/06 ,  A61P31/18

摘要： or a pharmaceutically acceptable salt thereof. Compounds of the present invention are useful for the treatment or prevention of HIV.

公开(公告)号：EP3352789A1

公开(公告)日：2018-08-01

申请号：EP16849829.3

申请日：2016-09-25

申请人： University of Florida Research Foundation, Inc.

发明人： YAMAMOTO, Janet, K.

IPC分类号： A61K39/12 ,  A61K39/395 ,  A61K39/00

CPC分类号： A61K39/21 ,  A61K9/0019 ,  A61K39/12 ,  A61K2039/5252 ,  A61K2039/54 ,  A61K2039/545 ,  A61K2039/552 ,  A61K2039/572 ,  A61K2039/575 ,  A61K2039/645 ,  A61P31/14 ,  A61P31/18 ,  C07K14/005 ,  C12N2740/15034 ,  C12N2740/15071 ,  C12N2740/16134 ,  C12N2740/16171 ,  C12N2740/16234 ,  C12N2740/16271 ,  C12N2740/16334 ,  C12N2740/16371

摘要： The subject invention concerns methods and materials for inducing an immune response in an animal or person against an immunodeficiency virus, such as HIV, SIV, or FIV. In one embodiment, a method of the invention comprises administering one or more antigens and/or immunogens to the person or animal wherein the antigen and/or immunogen comprises one or more evolutionarily conserved epitopes of immunodeficiency viruses. In one embodiment, the epitope is one that is conserved between HIV and FIV.

公开(公告)号：EP3349757A1

公开(公告)日：2018-07-25

申请号：EP16770854.4

申请日：2016-09-13

申请人： Gilead Sciences, Inc.

发明人： GELEZIUNAS, Romas ,  HESSELGESSER, Joseph, E. ,  KAUR, Jasmine ,  MURRY, Jeffrey, Patrick ,  SLOAN, Derek, Dean

IPC分类号： A61K31/519 ,  A61P31/18

CPC分类号： A61K31/519 ,  A61K39/3955 ,  A61K45/06 ,  A61K2300/00 ,  A61P31/18

摘要： Provided are methods, uses, pharmaceutical regimens, pharmaceutical compositions, and kits comprising modulators of TLR8 and pharmaceutically acceptable salts thereof, useful in treating HIV infections.

公开(公告)号：EP3337798A1

公开(公告)日：2018-06-27

申请号：EP16760188.9

申请日：2016-08-18

申请人： VIIV Healthcare UK (No.5) Limited

发明人： KADOW, John F. ,  NAIDU, B. Narasimhulu ,  TU, Yong

IPC分类号： C07D405/14 ,  C07D405/04 ,  C07D487/04 ,  C07D491/052 ,  C07D213/55 ,  A61K31/4545 ,  A61P31/18

CPC分类号： C07D213/55 ,  A61K31/4418 ,  A61K31/4433 ,  A61K31/4725 ,  A61K31/4741 ,  A61K31/506 ,  A61K31/519 ,  A61K31/5365 ,  A61P31/18 ,  C07D401/04 ,  C07D405/04 ,  C07D405/14 ,  C07D487/04 ,  C07D491/052 ,  C07D491/06

摘要： Disclosed are compounds of Formula I, including pharmaceutically acceptable salts, pharmaceutical compositions comprising the compounds, methods for making the compounds and their use in inhibiting HIV integrase and treating those infected with HIV or AIDS.